You are using an outdated browser. Please upgrade your browser to improve your experience.

Tchem
KLK14
Kallikrein-14

Protein Summary
Description
Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity. May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression including growth, invasion and angiogenesis. This gene encodes a member of the kallikrein subfamily of serine proteases that have diverse physiological functions such as regulation of blood pressure and desquamation. The altered expression of this gene is implicated in the progression of different cancers including breast and prostate tumors. The encoded protein is a precursor that is proteolytically processed to generate t ...more
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000391802
  • ENSP00000375678
  • ENSG00000129437

Symbol
  • KLKL6
  • KLK-L6
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
protein domain
0.58
biological term
0.51
cell line
0.49
trait
0.46
cell type or tissue
0.44


IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 54.77   (req: < 5)
Gene RIFs: 26   (req: <= 3)
Antibodies: 193   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 54.77   (req: >= 5)
Gene RIFs: 26   (req: > 3)
Antibodies: 193   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 8
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 17
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0